Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Orthofix Orthofix International N.V.
NEW YORK, July 30, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Orthofix International N.V. ("Orthofix" or the "Company") (NasdaqGS: OFIX). The investigation focuses on whether the Company and its executives violated federal securities laws.
On July 30, 2013, shares of Orthofix fell $4.32 or 15.77% during intraday trading to trade at $23.08 after the Company's announced on July 29, 2013 that it has delayed the filing of its second quarter 2013 10-Q after revenue recognition issues were identified by the Company's Audit Committee. The Company also announced that additional time is needed to review matters relating to revenue recognition for prior periods.
If you are aware of any facts relating to this investigation, or purchased shares of Orthofix you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email email@example.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
SOURCE Bronstein, Gewirtz & Grossman, LLC
More by this Source
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INTL FCStone, Inc.
Dec 19, 2013, 08:45 ET
Bronstein, Gewirtz & Grossman, LLC Announces Investigation of INSYS Therapeutics, Inc.
Dec 13, 2013, 10:26 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.